Similar articles for PMID: 18413402

Year	Number of Results
1994	1
1995	1
1996	1
1997	1
1998	3
1999	4
2000	3
2001	1
2002	5
2003	3
2004	13
2005	11
2006	15
2007	12
2008	9
2009	11
2010	19
2011	19
2012	20
2013	20
2014	28
2015	30
2016	29
2017	37
2018	40
2019	34
2020	31
2021	34
2022	22
2023	9
2024	0

1

Metabolic imaging of cerebral gliomas: spatial correlation of changes in O-(2-18F-fluoroethyl)-L-tyrosine PET and proton magnetic resonance spectroscopic imaging.

Stadlbauer A, Prante O, Nimsky C, Salomonowitz E, Buchfelder M, Kuwert T, Linke R, Ganslandt O. Stadlbauer A, et al. J Nucl Med. 2008 May;49(5):721-9. doi: 10.2967/jnumed.107.049213. Epub 2008 Apr 15. J Nucl Med. 2008. PMID: 18413402 Free article.

2

Proton magnetic resonance spectroscopic imaging in the border zone of gliomas: correlation of metabolic and histological changes at low tumor infiltration--initial results.

Stadlbauer A, Nimsky C, Buslei R, Pinker K, Gruber S, Hammen T, Buchfelder M, Ganslandt O. Stadlbauer A, et al. Invest Radiol. 2007 Apr;42(4):218-23. doi: 10.1097/01.rli.0000255812.61435.67. Invest Radiol. 2007. PMID: 17351427

3

Spatial Relationship of Glioma Volume Derived from ¹⁸F-FET PET and Volumetric MR Spectroscopy Imaging: A Hybrid PET/MRI Study.

Mauler J, Maudsley AA, Langen KJ, Nikoubashman O, Stoffels G, Sheriff S, Lohmann P, Filss C, Galldiks N, Kops ER, Shah NJ. Mauler J, et al. J Nucl Med. 2018 Apr;59(4):603-609. doi: 10.2967/jnumed.117.196709. Epub 2017 Aug 28. J Nucl Med. 2018. PMID: 28848036 Free PMC article.

4

Metabolic mapping of gliomas using hybrid MR-PET imaging: feasibility of the method and spatial distribution of metabolic changes.

Bisdas S, Ritz R, Bender B, Braun C, Pfannenberg C, Reimold M, Naegele T, Ernemann U. Bisdas S, et al. Invest Radiol. 2013 May;48(5):295-301. doi: 10.1097/RLI.0b013e31827188d6. Invest Radiol. 2013. PMID: 23296081

5

An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.

Grosu AL, Astner ST, Riedel E, Nieder C, Wiedenmann N, Heinemann F, Schwaiger M, Molls M, Wester HJ, Weber WA. Grosu AL, et al. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1049-58. doi: 10.1016/j.ijrobp.2010.07.002. Epub 2011 May 11. Int J Radiat Oncol Biol Phys. 2011. PMID: 21570201

6

Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy.

Floeth FW, Pauleit D, Wittsack HJ, Langen KJ, Reifenberger G, Hamacher K, Messing-Jünger M, Zilles K, Weber F, Stummer W, Steiger HJ, Woebker G, Müller HW, Coenen H, Sabel M. Floeth FW, et al. J Neurosurg. 2005 Feb;102(2):318-27. doi: 10.3171/jns.2005.102.2.0318. J Neurosurg. 2005. PMID: 15739561

7

Prognostic value of 18F-fluoroethyl-L-tyrosine PET and MRI in small nonspecific incidental brain lesions.

Floeth FW, Sabel M, Stoffels G, Pauleit D, Hamacher K, Steiger HJ, Langen KJ. Floeth FW, et al. J Nucl Med. 2008 May;49(5):730-7. doi: 10.2967/jnumed.107.050005. Epub 2008 Apr 15. J Nucl Med. 2008. PMID: 18413396 Free article.

8

Potential for differentiation of glioma recurrence from radionecrosis using integrated ¹⁸F-fluoroethyl-L-tyrosine (FET) positron emission tomography/magnetic resonance imaging: A prospective evaluation.

Sogani SK, Jena A, Taneja S, Gambhir A, Mishra AK, D'Souza MM, Verma SM, Hazari PP, Negi P, Jadhav GK. Sogani SK, et al. Neurol India. 2017 Mar-Apr;65(2):293-301. doi: 10.4103/neuroindia.NI_101_16. Neurol India. 2017. PMID: 28290392 Free article.

9

Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma.

Galldiks N, Stoffels G, Ruge MI, Rapp M, Sabel M, Reifenberger G, Erdem Z, Shah NJ, Fink GR, Coenen HH, Langen KJ. Galldiks N, et al. J Nucl Med. 2013 Dec;54(12):2046-54. doi: 10.2967/jnumed.113.123836. Epub 2013 Oct 24. J Nucl Med. 2013. PMID: 24159047 Free article.

10

Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.

Bette S, Gempt J, Delbridge C, Kirschke JS, Schlegel J, Foerster S, Huber T, Pyka T, Zimmer C, Meyer B, Ringel F. Bette S, et al. World Neurosurg. 2016 May;89:230-9. doi: 10.1016/j.wneu.2016.01.085. Epub 2016 Mar 9. World Neurosurg. 2016. PMID: 26855307

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

404 results

Results by year